(Q28288899)

https://api.crossref.org/works/10.1517%2F14656566.8.4.485

The taxoids. Comparative clinical pharmacology and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.485

Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.485

Phase II trial of a doxorubicin/docetaxel doublet for locally advanced and metastatic breast cancer: results from national surgical adjuvant breast and bowel project trial BP-57.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.485

Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.485

Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.485

Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.485

Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Gr

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.485

Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.485

Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.485

Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.485

Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.485

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.485

Adjuvant docetaxel for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.485

In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.485

Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.485

Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.485

Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.485

Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.485

Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer: a dose-finding study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.485

Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.485

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.485

Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.485